EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost‐Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in the United States

Ali A Abdeen iD, Turgay Ayer iD, Aanan Biswas, Chase J Wehrle, Sobia N Laique, Ali Aminian iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Ali A Abdeen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Liver Cirrhosis, Glucagon-Like Peptides, Metabolic Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The approval of new pharmacotherapies for metabolic dysfunction‐associated steatohepatitis (MASH) presents a critical need for value assessment. We evaluated the cost‐effectiveness of resmetirom, semaglutide and tirzepatide for U.S. adults with MASH and F2–F3 fibrosis. Materials and Methods We developed a Markov cohort model with a lifetime horizon from the perspective of a U.S. healthcare payer. The model simulated biopsy‐confirmed patients with MASH progressing through liver‐specific health states. Efficacy inputs for fibrosis regression and MASH resolution were obtained from a Bayesian network meta‐analysis. Each pharmacotherapy was compared individually against standard of care; a formal sequential incremental analysis across active therapies was not performed. Cost‐effectiveness was assessed against the standard of care using a $100 000/QALY willingness‐to‐pay threshold.

Results

In the base‐case analysis, tirzepatide had the largest QALY gain and the lowest incremental cost relative to standard of care, yielding an incremental cost‐effectiveness ratio of ($42 705/QALY). Semaglutide was also cost‐effective (ICER: $80 076/QALY). Resmetirom (ICER: $273 445/QALY) exceeded the WTP threshold. Drug price was the most influential parameter in sensitivity analyses; probabilistic sensitivity analysis showed a 99.5% probability of cost‐effectiveness for tirzepatide and 89.8% for semaglutide at $100 000/QALY.

Conclusions

At current U.S. prices, tirzepatide and semaglutide are cost‐effective for MASH with F2–F3 fibrosis, while resmetirom is not. The tirzepatide finding should be interpreted with caution, given that it is not yet FDA‐approved for MASH and its effect estimate is based on a network meta‐analysis of a phase 2 trial. Payer coverage and equitable access to MASH therapies require value‐based pricing strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisGlucagon-Like PeptidesMetabolic DiseasesHumansCost-Benefit AnalysisUnited StatesSemaglutideCost-Effectiveness AnalysisTirzepatideQuality-Adjusted Life YearsFemaleMaleMarkov ChainsAdult

Stichwörter der Autor:innen

GLP‐1GLP‐1 analoguecost‐effectivenessfatty liver diseaseliver

Substanzen

SemaglutideTirzepatideGlucagon-Like Peptides

Autor:innen und Institutionen

  • Department of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.
  • Information Systems and Operations Management Department, Kuwait University, Al-Shadadiya, Kuwait.
  • Division of Liver Transplantation, Cleveland Clinic, Cleveland, Ohio, USA.
  • Division of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio, USA.
  • Bariatric and Metabolic Institute, Department of General Surgery, Cleveland Clinic, Cleveland, Ohio, USA.

ORCID-Profile: Ali A Abdeen, Turgay Ayer, Ali Aminian

Zitieren

APA

Abdeen, A. A., Ayer, T., Biswas, A., Wehrle, C. J., Laique, S. N., & Aminian, A. (2026). Cost‐Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in the United States. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71020

Vancouver

Abdeen AA, Ayer T, Biswas A, Wehrle CJ, Laique SN, Aminian A. Cost‐Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in the United States. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71020

BibTeX
@article{Abdeen2026,
  author = {Abdeen, Ali A and Ayer, Turgay and Biswas, Aanan and Wehrle, Chase J and Laique, Sobia N and Aminian, Ali},
  title = {Cost‐Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in the United States},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71020}
}
Kostenlos starten →